PCM
MXCT icon

Portolan Capital Management’s MaxCyte MXCT Stock Holding History

Portolan Capital Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,135,613
Closed -$4.72M – 133
2024
Q4 		$4.72M Sell
1,135,613
-167,825
-13% -$634K 0.32% 94
2024
Q3 		$5.07M Sell
1,303,438
-384,212
-23% -$1.62M 0.37% 82
2024
Q2 		$6.62M Sell
1,687,650
-34,127
-2% -$147K 0.54% 66
2024
Q1 		$7.21M Sell
1,721,777
-1,035,472
-38% -$4.86M 0.55% 68
2023
Q4 		$13M Buy
2,757,249
+613,583
+29% +$2.39M 1.13% 24
2023
Q3 		$6.69M Buy
2,143,666
+493,789
+30% +$1.99M 0.63% 49
2023
Q2 		$7.57M Buy
1,649,877
+1,028,263
+165% +$4.73M 0.67% 42
2023
Q1 		$3.08M Buy
+621,614
New +$3.06M 0.29% 100

Other funds holding MXCT

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Portolan Capital Management's MXCT Position: Q1 2025 in Review

Portolan Capital Management sold out of MaxCyte (MXCT) in Q1 2025, closing a stake of 1,135,613 shares — an estimated $4.72M sold.

Portolan Capital Management first reported a position in MXCT in Q1 2023 and held it in 8 quarters. The position peaked at $13M in Q4 2023. 115 funds tracked by Wall St. Rank hold MXCT as of Q1 2025.

  • Portolan Capital Management reported no remaining MaxCyte position as of Q1 2025 after selling out during the quarter.
  • Portolan Capital Management sold 1,135,613 MaxCyte shares in Q1 2025, an estimated $4.72M.
  • Portolan Capital Management first reported a position in MaxCyte in Q1 2023 and held it in 8 quarters.
  • Portolan Capital Management's MaxCyte position peaked at $13M in Q4 2023.
  • 115 funds tracked by Wall St. Rank held MaxCyte as of Q1 2025.

Based on Portolan Capital Management's 13F filing for Q1 2025, filed 15 May 2025.